Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2015 Earnings Presentation

73 slides from Aspen Pharmacare's earnings presentation, December 2014

  1. Slide 1: Interim Results Presentation

    Interim Results Presentation For the six months ended 31 December 2014

  2. Slide 2: Highlights

    Highlights +47% +50% Gross revenue Operating profit R'million R'million 19 000 4 318 12 930 2 880 H1 2014 H1 2015 H1 2014 H1 2015 +128% +22% Cash from operating activities Normalised HEPS R'million Cents per share 2 687 569 468 1 176 H1 2014 H1 2015 H1 2014 H1 2015 2

  3. Slide 3: Abridged group statement of comprehensive income

    Abridged group statement of comprehensive income For the six months ended 31 December R’million H1 2015 H1 2014 % change Revenue 18 033 11 976 51% Cost of sales (9 562) (6 398) Gross profit 8 471 5 578 52% Net operating expenses (3 921) (2 519) EBITA 4 550 3 059 49% Amortisation (232) (179) Operatin

  4. Slide 4: Key Income statement indicators

    Key Income statement indicators Key indicators H1 2015 FY 2014 H1 2014 Gross margin 47.0% 46.5% 46.6% Normalised EBITA margin 24.4% 24.6% 24.8% 53% 54% 53% Effective tax rate 21.0% 21.3% 22.0% Net margin 13.6% 17.0% 16.1% COGS Net operating expenses 22% 19% 21% Amortisation 1% 1% 1% Net funding cost

  5. Slide 5: Net funding costs

    Net funding costs R’million H1 2015 H1 2014 Net interest paid (708) (328) Debt raising fees on acquisitions (66) (83) Net foreign exchange (losses)/gains (343) 49 Notional interest on financial instruments (88) (36) Net hyperinflationary adjustments (16) - Fair value gains/(losses) 14 (8) Total (1 2

  6. Slide 6: Reconciliation of earnings per share

    Reconciliation of earnings per share For six months ended 31 December Cents H1 2015 H1 2014 % change Basic EPS 539.1 423.4 27% Impairments 2.5 0.1 Other 0.1 0.7 Headline EPS 541.7 424.2 28% Restructuring costs 5.8 1.8 Capital raising fees 13.5 14.9 Transaction costs 8.1 29.2 Foreign exchange gain on

  7. Slide 7: Gross revenue by customer geography

    Gross revenue by customer geography 7

  8. Slide 8: Gross revenue bridge

    Gross revenue bridge 20 000 470 73 19 000 5 396 131 18 000 16 000 14 000 12 930 12 000 R'million 10 000 8 000 6 000 4 000 2 000 - - H1 2014 International Asia Pacific South Africa Sub-Saharan H1 2015 Africa 8

  9. Slide 9: Revenue analysis of major currencies

    Revenue analysis of major currencies Revenue analysis of major currencies Avg rate for Avg rate for Revenue Variance Rate benefit/ six months six months to H1 2015 % (loss) in R'm to Dec 2014 Dec 2013 in R'm Rand/EUR 13.99 13.73 2% 4 630 87 Rand/AUD 9.71 9.29 5% 4 069 176 Rand/USD 11.01 10.16 8% 1 5

  10. Slide 10: Analysis of major currency movements

    Analysis of major currency movements Analysis of major currency movements Avg rate for Avg rate for Closing rate - Variance Variance six months to six months to 27 Feb 2015 % % Dec 2014 Dec 2013 Rand/EUR 13.09 13.99 -6% 13.73 -5% Rand/AUD 9.13 9.71 -6% 9.29 -2% Rand/USD 11.69 11.01 6% 10.16 15% Rand

  11. Slide 11: Key currency movements vs USD

    Key currency movements vs USD Value of key currencies vs USD from June 2013 to December 2014 1.10 1.00 0.90 0.80 0.70 0.60 0.50 EUR AUD MXN BRL RUB ZAR 11

  12. Slide 12: Key currency movements vs USD

    Key currency movements vs USD Value of key currencies vs USD from June 2014 to February 2015 1.10 1.00 0.90 0.80 0.70 0.60 0.50 0.40 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 EUR AUD MXN BRL RUB ZAR 12

  13. Slide 13: Operating margins

    Operating margins Normalised EBITA margin % International Asia Pacific South Africa Sub-Saharan Africa Group 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% H1 2015 H1 2014 13

  14. Slide 14: Total assets

    Total assets 90 000 7 548 80 000 Property, plant and 7 151 equipment 70 000 Intangible assets 60 000 38 616 35 699 Goodwill 50 000 R'million 4 343 Inventory 40 000 6 642 6 289 18 933 30 000 Trade and other 10 275 10 124 receivables 20 000 5 973 9 627 10 371 Cash 4 101 10 000 5 464 8 226 10 936 6 019

  15. Slide 15: Capital expenditure

    Capital expenditure 2 000 1 800 1 600 1 400 1 017 R'million 1 200 1 000 800 1 329 600 667 400 470 809 652 200 - FY 2011 FY 2012 FY 2013 FY 2014 H1 2015 Capital Expenditure Forecast for rest of FY 2015 Depreciation Note: Depreciation for 2015 is the estimated full year forecast 15

  16. Slide 16: Borrowings

    Borrowings For six months ended 31 December R’million H1 2015 Net borrowings of R28.6 billion Opening balance 29 765 Cash flow from operating activities (2 687) Capital expenditure 809 International South Africa 51% 34% Proceeds from sale of assets (2 988) Acquisitions of businesses/brands 888 Payme

  17. Slide 17: Borrowings

    Borrowings Blended interest rates for borrowings as at 31 December 2014 Analysis of R28.6 billion net Weighted average rate borrowings Debt denomination p.a. ZAR 7.50% Net borrowings USD 2.75% AUD 4.85% Cash Key indicators H1 2015 FY 2014 Interest cover ratio 7.1x * 7.0x * Current borrowings Net bor

  18. Slide 18: Working capital and cash generation

    Working capital and cash generation R’million H1 2015 FY 2014 Net working capital 12 930 13 018 Net working capital excluding Oss 9 890 9 842 Working capital as a % of revenue 36% 37% Less: Attributable to Oss -6% -5% Working capital excluding Oss as a % of revenue 30% 32% Cash generation H1 2015 H1

  19. Slide 19: Group overview

    Group overview Revenue by customer geography R’million H1 2015 H1 2014 % change International 8 574 3 395 153% Asia Pacific 4 645 4 298 8% South Africa 4 310 3 840 12% Sub-Saharan Africa 1 471 1 397 5% Total 19 000 12 930 47%  Strong revenue growth driven by International division ◦ Largely acquisi

  20. Slide 20: International

    International Revenue by customer geography R’million H1 2015 H1 2014 % change Europe CIS 5 068 1 541 229% Commercial sales 3 415 547 525% Contract manufacturing sales 1 653 994 66% Latin America 2 618 1 203 118% Middle East North Africa 388 287 35% North America 500 364 37% - Commercial sales 301 2

  21. Slide 21: International Europe CIS

    International Europe CIS Revenue by customer geography R’million H1 2015 H1 2014 % change Commercial sales Western Europe 2 272 510 346% - Anticoagulants 1 331 - - Other 941 510 Eastern Europe and CIS 1 143 37 3009% - Anticoagulants 811 - - Other 332 37 API contract manufacturing sales 1 406 769 83%

  22. Slide 22: Aspen's entry into Europe

    International Aspen’s entry into Europe Aspen Mature Europe Distributor markets Manufacturing sites Aspen Emerging Europe CEE Aspen Emerging Russia CIS …420 reps in 21 markets Aspen representation – improved control over sales 22

  23. Slide 23: Sound platform set up in Europe CIS

    International Sound platform set up in Europe CIS  To perform in Europe CIS ◦ Need to perform in anticoagulants  Objective with anticoagulants ◦ Grow sales ◦ Grow margin − Covered under manufacture  Period to date dominated by ◦ Strategic plan ◦ Operational set up ◦ Regulatory transfers ◦ Supply

  24. Slide 24: Aspen's share of total injectable anticoagulant market is 19.2%

    International Aspen’s share of the total injectable anticoagulant market is 19.2% Europe CIS sales €1 600 €2.3 billion total anticoagulant injectables market €1 400 €1 200 €1 000 Millions €800 €600 €400 €200 €- LOVENOX FRAXIPARINE INNOHEP FRAGMIN ARIXTRA MONO OTHERS ASPEN EMBOLEX 2014 MAT JUNE FRAXI

  25. Slide 25: France: Prior downward GSK sales trend reversing

    International France: Prior downward GSK sales trend reversing Start of promotion 13.00% Partial stock Market share % of syringe unit packs out 12.50% 12.00% 11.50% 11.00% 10.50% 10.00% 9.50% 9.00% Source: IMS December 2014 25

  26. Slide 26: Germany: Prior downward sales trend stabilised

    International Germany: Prior downward sales trend stabilised Start of promotion 12.0 11.0 10.0 9.0 Market share in % 8.0 7.0 6.0 5.0 4.0 3.0 2.0 Total Aspen market share ARIXTRA FRAXIPARINE Source: IMS PhX December 2014, including parallel importing excluding hospital 26

  27. Slide 27: Germany: Mono-Embolex gives critical mass

    International Germany: Mono-Embolex gives critical mass, market share at 27.9% German injectable anticoagulant market € 300 € 250  Ease of use is key advantage ◦ Only LMWH product that offers patients weight-independent dosing € 200  Challenge: shelf life reduced to 12 months ◦ Working to improve

  28. Slide 28: Italy: Positive growth trend

    International Italy: Positive growth trend 4% 2% 0.8% 0.5% 1.7% 0% Value growth % -1.7% -2.4% -1.2% -2% -4% -7.1% -3.1% -6% -8% -8.7% -10% MAT NOVEMBER 2014 QTR NOVEMBER 2014 MONTH NOVEMBER 2014 Arixtra Market Arixtra market share change Source: IMS MIDAS November 2014  Upward sales value trend  G

  29. Slide 29: Poland: Positive value and share trend

    International Poland: Positive value and share trend Source: IMS December 2014  Sanofi gains during transitions now being reversed  Direct Aspen distribution to pharmacies and hospitals launched in September 2014 ◦ Closer to our customer base Poland is and will be a key market for Aspen 29

  30. Slide 30: Russia: Gaining share versus Clexane

    International Russia: Gaining share versus Clexane Sales in Rouble Brand name Sales Growth Lovenox/Clexane 2 112 508 -5% Fraxiparine 1 421 442 16% Heparin VIRI 972 181 20% Fragmin 253 810 18% Arixtra 197 329 7% Badyket 128 825 84% Anfibra 118 846 746% Enixum 113 425 0% - Total market 5 437 197 11% S

  31. Slide 31: Outlook – Europe CIS

    International Outlook – Europe CIS  Sales outlook ◦ Focus yielding initial green shoots − Too soon to confirm trend − Next 12 months will give better direction ◦ Russia performing in market but currency impacting  Margin improvements ◦ Will be driven through manufacture  Therapeutic area is perfo

  32. Slide 32: Outlook – Europe CIS

    International Outlook – Europe CIS  Sales performance will determine relative success ◦ Sole focus of rep teams ◦ Key additional indications submitted ◦ Investigator sponsored studies in female oncology − Unmet need  Mono-Embolex impetus ◦ Similar cost saving initiatives ◦ Has competitive advantag

  33. Slide 33: Europe CIS – API and FDF manufacture

    International Europe CIS – API and FDF manufacture  Objective of API and FDF manufacture ◦ COGS to drive sales and margins − Tender component − End to end control of supply chain ◦ Inefficiencies and input costs − Process and materials ◦ Economies of scale − Volumes cost per unit ◦ Drive globally m

  34. Slide 34: Europe CIS – API and FDF manufacture

    International Europe CIS – API and FDF manufacture APIs  Chemical APIs ◦ Built additional capacity in India/SA − Significant intermediate manufacture transferring calendar year 2015 ◦ Addresses current BRZO issues − Safety risk ◦ Drive cost competitiveness/capacity − Increased third party business

  35. Slide 35: Europe CIS – API and FDF manufacture

    International Europe CIS – API and FDF manufacture  Heparin API cost reduction initiatives ◦ Pulling through acquired stock − Depleted by May/June 2015 ◦ Thereafter price decreases > 30% − Obvious effect on Fraxiparine margin  Operational contribution ◦ Driving margin expansion ◦ Driving opportuni

  36. Slide 36: International Latin America

    International Latin America Revenue by customer geography R’million H1 2015 H1 2014 % change Brazil 413 413 0% Spanish Latin America 2 205 790 179% Nutritional sales 1 179 371 218% Pharmaceutical sales 1 026 419 145% Total 2 618 1 203 118%  Brazil sales flat ◦ In spite of supply interruptions − PE

  37. Slide 37: Latin America – Strategic commercial approach

    International Latin America – Strategic commercial approach  Regional commercial presence ◦ 700 pharma and nutritional reps in Mexico, Venezuela, Colombia, Ecuador, Chile, Peru, Central America and Caribbean  Current focus ◦ Build on the shift from retail to detail in the IMF business ◦ EBITA stra

  38. Slide 38: Latin America – Nutritionals

    International Latin America – Nutritionals Infant milk formula sales in Latin America USD’million 250 Transition to Aspen 234 228 206 200 187 190 150 100 50 0 2010 2011 2012 2013 2014  Successful transition to Aspen and implementation of commercial strategy 38

  39. Slide 39: Latin America – Global brands

    Latin America – Global brands Product sales performance - Spanish Latin America USD'million 7.0 25.0 6.0 20.2 20.0 5.0 15.8 13.7 15.0 4.0 3.2 3.3 3.0 2.7 2.7 2.7 10.0 2.3 2.0 2.1 1.7 1.6 5.0 1.0 1.2 0.8 0.8 - - 2012 2013 2014 Septrin Indocid Emselex/Enablex Aldomet Zyloprim/Zyloric  In market sales

  40. Slide 40: Latin America – Manufacturing in Vallejo

    International Latin America – Manufacturing in Vallejo  Product transitions ◦ Specialty formulations transferring from Nestlé ◦ Commercial batches for other Aspen markets  Margin improvement ◦ Global procurement synergies ◦ Overhead share with pharma ◦ Pulling back retail discounts ◦ Economies of

  41. Slide 41: Outlook - Latin America

    International Outlook - Latin America  Spanish Latin America ◦ Drive IMF growth and margin expansion ◦ Mexico key territory − Line extension of IMFs • Formula for pregnancy, growth formulas and adult nutrition ◦ Focus on anticoagulant portfolio ◦ Sustain current organic growth momentum  Brazil ◦ S

  42. Slide 42: Asia – targeted Aspen growth area

    Asia Pacific Revenue by customer geography R’million H1 2015 H1 2014 % change Australia and New Zealand 4 016 3 987 1% Asia 629 311 103% Total 4 645 4 298 8%  Australian performance impacted by divestments/licenses in prior year base ◦ Continuing, non-licensed business growing at 12%  Asian growth

  43. Slide 43: Australia - Performance

    Asia Pacific Australia - Performance Revenue by customer geography R’million H1 2015 H1 2014 % change Base 2 664 2 382 12% Contract manufacturing 191 191 0% Licensed products 287 393 -27% Terminating licenses and 356 577 -38% divested/discontinued products Nutritionals 518 444 17% Total 4 016 3 987

  44. Slide 44: Australian pharmaceutical sector

    Asia Pacific Australian pharmaceutical sector  As at 31 December 2014 ◦ Stagnant at AUD14.1 billion ◦ Market value growth of -0.9% ◦ Volume growth of +4.1%  Aspen in Australia ◦ Value share remains at 5% ◦ 1 in 5 scripts generated is for an Aspen distributed product ◦ Leading generic company with

  45. Slide 45: Australia

    Asia Pacific Australia  Managing and mitigating impact of price cuts ◦ Continue to address cost of goods for impacted products ◦ Brand premiums ◦ Roll out of pipeline − Performance boosted by product launches ◦ Increase in customer base − Conversion of banner groups ◦ Infant milk formula not expose

  46. Slide 46: Australia - Nutritionals business

    Asia Pacific Australia - Nutritionals business  Revenue of R515m in H1 2015  Growth of 17% in revenue  Biggest contributors to revenue are stages 1 and 2 ◦ Stages 3, 4 and new launches continue to perform  Diversification of channels ◦ Placing product in additional channels  Strategic investmen

  47. Slide 47: Outlook - Australia

    Asia Pacific Outlook - Australia  Focus on base pharma business ◦ Retain current growth trajectory  Nutritional business to continue performing ◦ Investing in commercial activities ◦ Transitioning manufacture to NZNM  Portfolio review on-going ◦ Business integrated − Facilitates strategic overvie

  48. Slide 48: Asia – Revenue by geography

    Asia Pacific Asia – Revenue by geography R630m total revenue Rest of Asia 9% Japan 40% China 5% Hong Kong 5% Indonesia 6% Philippines 20% Taiwan 7% Malaysia 8%  Japan now the largest contributor in Asia  Revenue growth of 103% over prior year  Strong organic growth ◦ About a third 48

  49. Slide 49: Asia

    Asia Pacific Asia  Aspen’s subsidiaries continue to perform Philippines Malaysia Taiwan • +47% revenue • +42% revenue • +43% revenue growth growth growth • Started trading • Started trading • Finished first in 2012 in 2013 year of trading • 135 staff • 29 staff • 13 staff  Expansion of Aspen footp

  50. Slide 50: Asia – Aspen Japan

    Asia Pacific Asia  Aspen Japan ◦ Pharmaceutical business license granted ◦ Entered into strategic collaboration with GSK − 75% Aspen owned, 25% GSK − Aspen’s entire portfolio in Japan − Selected GSK products − Access to authorised generics of GSK portfolio ◦ Country CEO & management team in place ◦

  51. Slide 51: South Africa

    South Africa Revenue by customer geography R’million H1 2015 H1 2014 % change Pharmaceutical Private sector 2 385 2 165 10% Public sector 835 841 -1% - ARV tender 546 525 4% - Other tenders 289 316 -9% Consumer 664 512 30% Finished form and API manufacturing 426 322 32% Total 4 310 3 840 12%  Susta

  52. Slide 52: South Africa Performance

    South Africa Performance  Strong H1 performance in private pharma driven by ◦ Base volume growth ◦ Top brands’ performance ◦ Shifting market dynamics towards generics − Product launches added to impetus − Co-marketing agreements for key generic molecules  Public sector flat ◦ ARV volumes recovered

  53. Slide 53: South Africa Private pharmaceutical sector

    South Africa Private pharmaceutical sector  As at 31 December 2014 ◦ Valued at R31 billion ◦ Market value growth of +4.7% ◦ Driven by generics growth  Aspen in South Africa ◦ Growing ahead of market ◦ Value share at 16% − 4 of top 15 brands are Aspen products ◦ Leading generic company with 29% of

  54. Slide 54: South Africa Public sector

    South Africa Public sector  ARV revenue at R546m recovered from prior half  New ARV tender ◦ 3 year contract commencing 1 April 2015 ◦ Awarded 24% of triple combination volumes with 3 other suppliers − One importer Mylan − Ranbaxy, Cipla represented local manufacture − Demand hard to predict, give

  55. Slide 55: Consumer – Infant milk formula

    South Africa Consumer – Infant milk formula  Acquisition of Nestlé SMA, S26 approved ◦ Process protracted ◦ Entity loss making  Limited players ◦ Nestlé 72% ◦ Aspen 24% ◦ Abbott 3% ◦ Other 1%  S26 ◦ Competition process delay ◦ Market share loss ◦ Stock outs  Infacare ◦ Material volume increases

  56. Slide 56: Consumer – Infant milk formula

    South Africa Consumer – Infant milk formula  S26 ◦ Now recovering ◦ Divisions merged − Operational synergies being realised − Global procurement, commodity decreases have margin impact − Improved profit flow anticipated in H2 results  Infacare ◦ Growth trajectory to continue  Aspen business integ

  57. Slide 57: South Africa Outlook

    South Africa Outlook  Pharma ◦ Private sector to sustain − SEP increase needed − H2 growth % over prior year to increase − Volume growth to continue − Public sector unpredictable  Currency fluctuations ◦ SEP set in Rands ◦ Costs largely $ denominated ◦ Depreciating currency stresses margins  Cons

  58. Slide 58: Sub-Saharan Africa

    Sub-Saharan Africa Regional revenue growth rates Gross sales R1 471m (2014: R1 397m) West Africa +8% East Africa 34% West Africa 55% East Africa -4% Southern Africa Southern Africa +24% 11% Revenue growth of 5% Normalised EBITA growth of 12% 58

  59. Slide 59: Sub-Saharan Africa Performance and Outlook

    Sub-Saharan Africa Performance and Outlook  Collaboration growth restricted ◦ Single digit growth ◦ Performance negatively impacted by supply challenges for key products − Sales impact > R100m − East Africa most impacted ◦ Nigeria, most significant country in the Collaboration − Political challenge

  60. Slide 60: Strategy and Outlook: anticoagulants

    Strategy and Outlook Drive a global leadership position in anticoagulants  Target global growth in both sales and margin  Products underutilised in emerging markets ◦ Aspen has core strength here ◦ Markets will grow ◦ Aspen already performing  In developed markets Aspen has dedicated focus – buil

  61. Slide 61: Strategy and Outlook: global IMF business

    Strategy and Outlook Focus on global IMF business ◦ Grow existing markets ◦ Improve margin returns ◦ Establish new markets  Existing markets ◦ Strategic shift to detail strategy ◦ Aspen’s strength  Improve margin returns ◦ Rationalisation of acquired operating structures ◦ Global synergies/access

  62. Slide 62: Strategy and Outlook: IMF in China

    Strategy and Outlook IMF in China  Aspen is currently reviewing options ◦ Local partnering − Market large and expanding − Opaque and challenging  Aspen has ◦ Manufacturing capability − Secure supply line to quality milk manufacture − Through NZNM Aspen has accredited access into China • One of onl

  63. Slide 63: Strategy and Outlook: acquisitions and divestments

    Strategy and Outlook Acquisitive/divestment activity ◦ Global pharma industry is fluid ◦ Aspen well poised to take advantage ◦ Geographic/operational strengths  Continue with our portfolio review across all regions ◦ Reduce complexity ◦ Drive focus, reduce bureaucracy ◦ Further divestments possible

  64. Slide 64: Summary and Prospects

    Summary and Prospects  Strong operational performance ◦ Strong cash flow  All key indicators positive ◦ Acquisitions successfully bedded down ◦ Meaningful impact  H2 has similar drivers to H1 ◦ Anticipate improved EBITA – extraction of synergies ◦ Profit before tax impacted by forex/currency  Cu

  65. Slide 65: Summary and Prospects

    Summary and Prospects  Increased geographic base and infrastructure ◦ Created broader acquisitive opportunities ◦ Improved skills base/niche capabilities ◦ Asia is a core focus area  Material organic profitability to be extracted ◦ Synergies largely from acquisitions ◦ Will be realised from now th

  66. Slide 66: Q&A

    Q&A al

  67. Slide 67: Disclaimer

    Disclaimer Cautionary regarding forward-looking statements This presentation has been prepared by Aspen Pharmacare Holdings Limited based on information available to it as at the date of the presentation. This presentation may contain prospects, projections, future plans and expectations, strategy a

  68. Slide 68: Appendices

    Appendices Appendix 1: Group statement of financial position Appendix 2: Extract from group statement of cash flows Appendix 3: Segmental revenue and normalised EBITA Appendix 4: Corporate activity Appendix 5: Institutional investors 68

  69. Slide 69: Group statement of financial position

    Appendix 1 Group statement of financial position As at 31 December R’million H1 2015 H1 2014 ASSETS Non-current assets 54 434 49 741 Property, plant and equipment 7 548 6 058 Intangible assets 38 616 36 334 Goodwill 6 289 6 183 Contingent environmental indemnification assets 699 725 Other non-curren

  70. Slide 70: Extract from group statement of cash flows

    Appendix 2 Extract from group statement of cash flows For the six months ended 31 December R’million H1 2015 H1 2014 % change Cash operating profit 4 917 3 278 50% Changes in working capital (655) (1 113) Cash generated from operations 4 262 2 165 97% Net finance costs paid (1 030) (297) Tax paid (5

  71. Slide 71: Segmental revenue and normalised EBITA

    Appendix 3 Segmental revenue and normalised EBITA Gross revenue by region Normalised EBITA by region 3% 4% 4% 5% 100% 100% 9% 10% 9% 8% 90% 90% 24% 21% 80% 24% 23% 80% 35% 70% 35% 70% 60% 55% 21% 60% 23% 60% 25% 27% 50% 50% 34% 40% 40% 37% 6% 30% 13% 30% 46% 53% 20% 40% 47% 20% 31% 27% 10% 23% 18% 1

  72. Slide 72: Corporate activity

    Appendix 4 Corporate activity  Disposal of Fondaparinux molecules in the United States to Mylan ◦ Prompted by lack of knowledge of the US generic sector ◦ USD300 million consideration ◦ USD37.5 million remains in escrow until March 2015  Acquisition of 50% of New Zealand New Milks ◦ Supply of infa

  73. Slide 73: Institutional investors

    Appendix 5 Institutional investors 100% 90% 80% 70% Southern Africa 60% North America 50% Europe 40% Asia Pacific 30% Middle East 20% 10% 0% June 2011 June 2012 June 2013 June 2014 Dec 2014 73

Aspen Pharmacare Holdings — H1 2015 Earnings Presentation on 6ix